Epigenetics and psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 4, 2012, Pages 399-403

  Zhang, P ^a   Su, Y ^a   Lu, Q ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

DNA METHYLATION; EPIGENETICS; GENE SILENCING; GENETIC SUSCEPTIBILITY; HISTONE MODIFICATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW;

DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; PSORIASIS;

EID: 84858865330     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04261.x     Document Type: Review

References (61)

1. Waddington CH,. The epigenotype. Endeavour 1942; 1: 18-20.
2. Probst AV, Dunleavy E, Almouzni G,. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol 2009; 10: 192-206.
3. Bird A,. Perceptions of epigenetics. Nature 2007; 447: 396-398. (Pubitemid 46816744)
4. Grolleau-Julius A, Ray D, Yung RL,. The role of epigenetics in aging and autoimmunity. Clin Rev Allergy Immunol 2010; 39: 42-50.
5. Kaminsky ZA, Tang T, Wang SC, et al. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet 2009; 41: 240-245.
6. Egger G, Liang G, Aparicio A, Jones PA,. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-463. (Pubitemid 38715140)
7. Holliday R, Pugh JE,. DNA modification mechanisms and gene activity during development. Science 1975; 187: 226-232.
8. Robertson KD,. DNA methylation and human disease. Nat Rev Genet 2005; 6: 597-610. (Pubitemid 41044297)
9. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428. (Pubitemid 34587077)
10. Goll MG, Kirpekar F, Maggert KA, Yoder JA, Hsieh CL, Zhang X,. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006; 311: 395-398. (Pubitemid 43132667)
11. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N,. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-191. (Pubitemid 28248804)
12. Jones PA, Takai D,. The role of DNA methylation on mammalian epigenetics. Science 2001; 293: 1068-1070. (Pubitemid 32758075)
13. Cuthbert GL, Daujat S, Snowden AW, Erdjument-Bromage H, Hagiwara T, Yamada M,. Histone deimination antagonizes arginine methylation. Cell 2004; 118: 545-553. (Pubitemid 39179708)
14. Gregory PD, Wagner K, Horz W,. Histone acetylation and chromatin remodeling. Exp Cell Res 2001; 265: 195-202. (Pubitemid 32980207)
15. Bernstein BE, Meissner A, Lander ES,. The mammalian epigenome. Cell 2007; 128: 669-681. (Pubitemid 46273573)
16. Esteller M,. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
17. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40: 741-750. (Pubitemid 351748874)
18. Lee RC, Feinbaum RL, Ambros V,. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854. (Pubitemid 24014542)
19. Wightman B, Ha I, Ruvkun G,. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75: 855-862. (Pubitemid 24014543)
20. Friedman RC, Farh KK, Burge CB, Bartel DP,. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
21. Chen CZ, Li L, Lodish HF, Bartel DP,. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86. (Pubitemid 38055775)
22. Lindsay MA,. MicroRNAs and the immune response. Trends Immunol 2008; 29: 343-351.
23. Xiao C, Rajewsky K,. MicroRNA control in the immune system: basic principles. Cell 2009; 136: 26-36.
24. Medina PP, Slack FJ,. MicroRNAs and cancer: an overview. Cell Cycle 2008; 7: 2485-2492.
25. Zhang C,. MicroRNAs: role in cardiovascular biology and disease. Clin Sci (Lond) 2008; 114: 699-706. (Pubitemid 351799329)
26. Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS ONE 2007; 2: e610.
27. Christophers E,. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320. (Pubitemid 34204344)
28. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271. (Pubitemid 47069537)
29. Gaspari AA,. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54: S67-S80. (Pubitemid 43243477)
30. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
31. Davidson A, Diamond B,. Autoimmune diseases. N Engl J Med 2001; 345: 340-350.
32. Henseler T, Christophers E,. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456. (Pubitemid 15016489)
33. Krueger GG, Duvic M,. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994; 102: 14S-18S. (Pubitemid 24210359)
34. Kastelan M, Prpic Massari L, Gruber F, et al. Perforin expression is upregulated in the epidermis of psoriatic lesions. Br J Dermatol 2004; 151: 831-836. (Pubitemid 39482117)
35. Giblin PA, Lemieux RM,. LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics. Curr Pharm Des 2006; 12: 2771-2795. (Pubitemid 44184635)
36. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y,. Epigenetics and autoimmunity. J Autoimmun. 2010; 34: J207-J219.
37. Prinz JC,. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 257-270. (Pubitemid 36575644)
38. Zarrabeitia MT, Farinas MC, Rodriguez-Valverde V, Riancho JA, Llaca HF,. T and B cell function in psoriasis and psoriatic arthropathy. Allergol Immunopathol (Madr) 1989; 17: 155-159.
39. Schon M, Denzer D, Kubitza RC, Ruzicka T, Schon MP,. Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J Invest Dermatol 2000; 114: 976-983. (Pubitemid 30252720)
40. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figneiredo A, Quintanilha A, Teixeira F,. Erythrocyte damage in mild and severe psoriasis. Br J Dermatol 2004; 150: 232-244. (Pubitemid 38352460)
41. Zhang K, Zhang R, Li X, Yin G, Niu X,. Promoter methylation status of p15 and p21 genes in HPP-CFCs of bone marrow of patients with psoriasis. Eur J Dermatol 2009; 19: 141-146.
42. Zhang RL, Niu XP, Li XH, Zhang KM, Yin GH,. CFU-HPP colony formation of bone marrow hematopoietic proginitor cells in psoriatic patients and methylation of p16 gene promotor in CFU-HPP colony cells [Article in Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 780-784.
43. Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ,. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997; 151: 1321-1329. (Pubitemid 27479762)
44. Chen M, Chen ZQ, Cui PG, et al. The methylation pattern of p16INK4a gene promoter in psoriatic epidermis and its clinical significance. Br J Dermatol 2008; 158: 987-993. (Pubitemid 351521461)
45. Zhang P, Su Y, Chen H, Zhao M, Lu Q,. Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. J Dermatol Sci 2010; 60: 40-42.
46. Ruchusatsawat K, Wongpiyabovorn J, Shuangshoti S, Hirankarn N, Mutirangura A,. SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J Mol Med 2006; 84: 175-182. (Pubitemid 43201258)
47. Kim YI, Logan JW, Mason JB, Roubenoff R,. DNA hypomethylation in inflammatory arthritis: reversal with methotrexate. J Lab Clin Med 1996; 128: 165-172. (Pubitemid 27506445)
48. Tovar-Castillo LE, Cancino-Díaz JC, García-Vázquez F, et al. Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int J Dermatol 2007; 46: 239-246. (Pubitemid 46390278)
49. Blander G, Bhimavarapu A, Mammone T, et al. SIRT1 promotes differentiation of normal human keratinocytes. J Invest Dermatol 2009; 129: 41-49.
50. Haigis MC, Guarente LP,. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-2921. (Pubitemid 44771725)
51. Trimarchi JM, Lees JA,. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 3: 11-20. (Pubitemid 135709914)
52. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR,. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 1997; 94: 7245-7250. (Pubitemid 27345300)
53. Wu L, Timmers C, Maiti B, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 2001; 414: 457-462. (Pubitemid 34173728)
54. Vojinovic J, Damjanov N,. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 2011; 17: 397-403.
55. Faraco G, Cavone L, Chiarugi A,. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol Med 2011; 17: 442-447.
56. Reilly CM, Regna N, Mishra N,. HDAC inhibition in Lupus models. Mol Med 2011; 17: 417-425.
57. McLaughlin F, La Thangue NB,. Histone deacetylase inhibitors in psoriasis therapy. Curr Drug Targets Inflamm Allergy 2004; 3: 213-219. (Pubitemid 38832753)
58. Kubo M, Hanada T, Yoshimura A,. Suppressors of cytokine signaling and immunity. Nat Immunol 2003; 4: 1169-1176. (Pubitemid 37540685)
59. Taganov KD, Boldin MP, Chang KJ, Baltimore D,. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486. (Pubitemid 44267285)
60. Tili E, Michaille JJ, Cimino A, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179: 5082-5089.
61. Zibert JR, Lá̧vendorf MB, Litman T, Olsen J, Kaczkowski B, Skov L,. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010; 58: 177-185.